Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Lu, Ping  [Clear All Filters]
Journal Article
Hou H, Sun H, Lu P, Ge C, Zhang L, Li H, Zhao F, Tian H, Zhang L, Chen T, et al. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse xenograft models of human hepatocellular carcinoma. Mol Cancer Ther. 2013.
He R, Shi J, Xu D, Yang J, Shen Y, Jiang Y-S, Tao L, Yang M, Fu X, Yang J-Y, et al. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Cancer Lett. 2022:215693.
Lu P, Xu J, Shen X, Sun J, Liu M, Niu N, Wang Q, Xue J. Spatiotemporal role of SETD2-H3K36me3 in murine pancreatic organogenesis. Cell Rep. 2024;43(2):113703.
He D, Zhang J, Wu W, Yi N, He W, Lu P, Li B, Yang N, Wang D, Xue Z, et al. A novel immunodeficient rat model supports human lung cancer xenografts. FASEB J. 2018:fj201800102RR.
Hu J-J, Yin Z, Shen W-L, Bin Xie Y-, Zhu T, Lu P, Cai Y-Z, Kong M-J, Heng BChin, Zhou Y-T, et al. Manipulating Stem Cells to Treat Calcification Pharmacological Regulation of in-situ Tissue Stem Cells Differentiation for Soft Tissue Calcification Treatment. Stem Cells. 2016.
Niu N, Lu P, Yang Y, He R, Zhang L, Shi J, Wu J, Yang M, Zhang Z-G, Wang L-W, et al. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis. Gut. 2019.
Liu F, Yao Z, Jiao Q, Cao L, Feng H, Yao S, Li Y, Lu P. Inducing Specific Immune Tolerance to Prevent Type 1 Diabetes in NOD Mice. Pancreas. 2016.
Shen X, Chen Y, Liu M, Shi J, Tang Y, Yang X, Xu D, Yao H, Lu P, Sun Y, et al. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Biochem Biophys Res Commun. 2022;615:9-16.
Shi J, Lu P, Shen W, He R, Yang M-W, Fang Y, Sun Y-W, Niu N, Xue J. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Cancer Lett. 2019.